Camrelizumab
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-CAMRELIZUMAB |
|---|---|
| Tipo | Fármaco |
| Aliaces | AiRuiKaSHR-1210Камрелізумаб |
| Situación | reviewed 2026-07-11 | pending_clinical_signoff |
| Enfermedades | DIS-NPC |
| Fuentes | SRC-CAPTAIN-1ST-YANG-2021 |
Datos sobre drogas
| Clase | Anticuerpo monoclonal IgG4 humanizado anti-PD-1 (inhibidor del punto de control inmune) |
|---|---|
| Mecanismo | Humanized IgG4 monoclonal antibody binding PD-1 on activated T cells, blocking PD-1/PD-L1 and PD-1/PD-L2 interactions and restoring cytotoxic T-cell antitumor activity. Same general anti-PD-1 mechanistic class as pembrolizumab, nivolumab, and toripalimab. Studied specifically in recurrent/metastatic nasopharyngeal carcinoma (CAPTAIN-1st) combined with gemcitabine + cisplatin, as well as in multiple other Chinese-registered indications (hepatocellular carcinoma, NSCLC, esophageal SCC, classical Hodgkin lymphoma). |
| Dosificación típica | Per the CAPTAIN-1st trial protocol: camrelizumab 200 mg IV every 3 weeks, combined with gemcitabine + cisplatin (GP) for up to 6 cycles, followed by camrelizumab monotherapy (200 mg IV q3w) until disease progression, unacceptable toxicity, or up to 2 years total. STUB — dosing drafted from trial-protocol recall; pending Clinical Co-Lead confirmation against the primary source. |
| Ucrania registrada | Falso |
| NSZU reembolsado | Falso |
Notas
STUB — draft entity pending Clinical Co-Lead sign-off (CHARTER §6.1; currently dev-mode-exempted). Anti-PD-1 backbone alternative for NPC metastatic 1L combination per CAPTAIN-1st (Yang Y et al., Lancet Oncol 2021): camrelizumab + gemcitabine + cisplatin significantly improved PFS vs chemo alone in treatment-naive recurrent/metastatic NPC. NOT FDA-approved (China/NMPA-approved only) — distinguishes it from toripalimab (DRUG-TORIPALIMAB), the FDA-approved alternative for the identical clinical scenario. Reuse this entity rather than duplicate. RCCEP is a genuinely distinctive camrelizumab-class AE not shared with pembrolizumab/nivolumab/toripalimab — worth flagging for patient counseling.
Utilizado por
Fármaco
DRUG-TORIPALIMAB- Toripalimab
Esquema terapéutico
REG-NPC-GC-CAMRELIZUMAB- Camrelizumab + gemcitabine + cisplatin (CAPTAIN-1d) — 1L recurrente/nasofaringe metastásica...